CHARM Therapeutics Doses First AML Patient in CHM-029 Trial

CHARM Therapeutics announced Wednesday that it has initiated dosing and completed enrollment of the first cohort in a Phase I/II clinical trial evaluating CHM-029, its lead drug candidate for acute myeloid leukemia (AML). The London-based clinical-stage biotechnology company described the milestone as a significant step in its effort to address treatment resistance in one of the most aggressive blood cancers.

CHM-029 is designed as a best-in-class menin inhibitor, a class of drugs that targets a protein interaction implicated in certain forms of AML. The compound is notable for another reason beyond its therapeutic target: CHARM says it is the first molecule designed using a protein-ligand co-folding model to advance into human clinical studies, representing a landmark for AI-assisted drug discovery methods.

Read more 360 Orthopedics Earns Florida Workers' Comp Center of Excellence Tag →

The Phase I/II trial structure is standard for early-stage oncology research, with the first phase focused on establishing safety and tolerability across escalating doses before the second phase assesses efficacy in a broader patient population. Full enrollment of the opening cohort signals that the study is progressing on schedule, though results from the early safety phase are not yet available.

AML is a rapidly progressing cancer of the blood and bone marrow with historically poor outcomes, particularly in patients who develop resistance to existing therapies. CHARM's focus on the menin inhibitor mechanism reflects broader industry interest in targeting the genetic drivers of relapsed or refractory AML, a segment with significant unmet medical need.

Continue reading at GlobeNewswire - Industry News on Financial Services.